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Summary Cell proliferation rate is a well-established prognostic factor in cancer, but it has not been
considered to identify the risk group of childhood acute lymphoblastic leukaemia (ALL) at presentation. We
carried out a study to demonstrate the prognostic importance of the rapidity of cell proliferation in patients
with ALL. To measure the rapidity of cell proliferation we used the parameter relative to the area of
silver-stained nucleolar organiser regions (AgNORs) as evaluated by morphometric analysis on smeared
marrow blast cells. The mean AgNOR area of leukaemic marrow cells was measured in 119 children. By using
a cut-off value of 3 gim2, we identified a group of 91 children with low proliferating blast activity (mean
AgNOR value 2.11 jum2) and a group of 28 children with high proliferating activity (mean AgNOR value
3.29gtm2). The group of patients with a mean AgNOR value > 3 ltm2 was characterised by a higher number
of deaths, more frequent relapse and shorter time interval to relapse than the group of patients with mean
AgNOR value <3 gm2 (P<0.01). Multivariate analysis performed to include T-cell immunophenotype, FAB
morphology, leucocyte count and presence of mediastinal mass showed that the mean AgNOR value was the
only independent predictor of unfavourable event-free survival probability (P>0.01). Our results indicate that
the rapidity of marrow blast cell proliferation is an important prognostic parameter in childhood ALL and
should be routinely introduced in the group risk definition.
Acute lymphoblastic leukaemia (ALL) is the most frequent
tumour of childhood. Using current therapeutic protocols,
complete remission is possible in 90% of children, about
70% of whom are alive 5 years later. The most important
well-established factors affecting prognosis are leucocyte
count, age, cytogenetic abnormalities, leukaemic lymphoblast
immunophenotype and sex. A combination of these factors
allows identification of standard- and high-risk groups, the
latter being characterised by less remission and lowest sur-
vival rates. Therapeutic protocols applied to children are
different according to the group in which they have been
included. There is evidence that a more intensive therapy can
improve results in the high-risk group. A more precise
identification of those children with poor prognostic features
should greatly increase the probability of applying more
effective therapeutic approaches.
Cell kinetics has rarely been investigated for prognostic
purposes in ALL, in contrast to many other types of human
cancers, in which an association between cell proliferating
activity and clinical outcome has been found. Cell prolifera-
tion rate has not been considered among the prognostic
factors for treatment of ALL (Hoelzer et al., 1988; Champlin
& Gale, 1989), probably because of equivocal results obtain-
ed regarding the relationship between cell kinetics and prog-
nosis (Murphy et al., 1977; Scarffe, et al., 1980; Dow et al.,
1982). In order to ascertain the prognostic importance of
pretreatment cell kinetics measurement in ALL, we evaluated
the rapidity of cell proliferation in marrow leukaemic lym-
phoblasts by measuring the quantity of silver-stained
nucleolar organiser regions (AgNOR) proteins. The quantity
of AgNOR proteins, a parameter of cell proliferative activity
recently introduced in tumour pathology (Crocker, 1990;
Derenzini & Ploton, 1991), has been shown to be directly
related to the cell doubling time (Trere et al., 1989; Derenzini
et al., 1990). For this purpose, smeared marrow preparations
from 119 children with ALL were stained, at presentation,
with the silver method for the AgNOR proteins (Ploton et
al., 1986) and evaluated by image cytometry. This study was
started in 1988 with the aim ofcorrelating the rapidity of cell
proliferation at presentation with the rate of event-free sur-
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vival. The importance of AgNOR values as a prognostic
parameter was also compared with that of other well-esta-
blished pretreatment prognostic features.
Materials and methods
Patients
From January 1989 to March 1991, out of 642 ALL children
recruited consecutively in AIEOP large-scale trials, a random
sample of 119 (18.5%) were evaluated for this study on the
basis of bone marrow smear availability after centralised
standard morphological and cytochemical confirmation pro-
cedures of diagnosis were performed. Within this subgroup
of patients no statistical differences were found as far as
major ALL prognostic factors (white cell count, immuno-
phenotype, age and sex, cytogenetic markers) were con-
cerned, compared with the total 642 patients recruited.
The diagnosis was based on the criteria defined by the
'BFM Family' Cooperative Group (van der Does van der
Berg et al., 1992). Cell-surface antigens were detected by indirect immunofluorescence with an extensive panel of
mono- and polyclonal antibodies according to a previously described method (Basso et al., 1992).
Complete remission (CR) was defined as the absence of
leukaemic blasts in blood and in cerebrospinal fluid, with less
than 5% lymphoblasts in marrow aspirate, together with the
absence of signs or symptoms of leukaemia.
Relapse (REL) was diagnosed when bone marrow con-
tained >25% unequivocal malignant blast cells or when
extramedullary documented leukaemia occurred after CR.
Forty-two patients were treated according to AIEOP ALL
87 protocols (Vecchi et al., 1990) while the remaining patients received a different BFM-oriented protocol, called AIEOP
ALL 88 (Rossi et al., 1991).
Patient data were collected interactively by patient-oriented
and protocol-specific reporting forms filled in prospectively
by the responsible clinician. Information was stored, con-
trolled and analysed by VENUS, a software facility integrated
system running on an IBM mainframe at the North-East
Italian University Computing Center (CINECA).
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NOR silver staining and measurements ofinterphase AgNORs
NOR silver staining was carried out on the cytological sam-
ples using a solution of one volume of 2% gelatine in 1%
aqueous formic acid and two volumes of 50% silver nitrate
(Ploton et al., 1986). Silver staining was performed for
10min at 37°C.
Morphometric analysis of interphase AgNOR areas of
marrow blasts was performed by using a specific program
(IM 5200) of a computer-assisted image analysis system
(Sistema MONO, Immagini e Computer, Milan, Italy). The
principal stages of image processing were as follows. A field
was selected by the operator within the circled area using a
40 x objective lens. The selected image was then captured
into digital memory and visualised on the monitor of the
image analyser. Here the silver-stained structures appeared as
dark dots, of different shape and sizes, more or less regularly
distributed throughout the nucleolus and easily distin-
guishable from the lighter background. By moving the mouse
on the digitiser tablet, the operator interactively defined the
grey threshold which permitted automatic quantification of
the silver-stained structures only. On the colour monitor it
was possible to check the structures covered by each grey
threshold, which were stained red on the original image. The
morphometric analysis was performed by measuring the
AgNOR area of the single cells. For each case the AgNOR
area was measured in 100 blast cells and the mean value of
the recorded data was defined. We limited our morphometric
analysis to 100 nuclei per patient since we have found that,
even in heterogeneous samples, after 70-80 measurements
both the mean value and the standard deviation are main-
tained nearly constant.
Statistical analysis
Patient distribution according to AgNOR area value by
occurrence of death or disease relapse was tested by the
chi-square test. AgNOR area value was compared with other
clinical and laboratory features at diagnosis by computing
the Pearson correlation coefficient for continuous variables
(age, leucocyte count, marrow infiltration, peripheral blasts,
hepatomegaly, splenomegaly and platelet number) and its
mean by Student's t-test for comparison of categorical (sex,
FAB morphology and immunophenotype) variables.
Survival (SUR) and event-free survival (EFS) were
estimated by the Kaplan-Meier method and updated to June
1992. Time on study or time to terminal event was calculated
from the day of diagnosis for both SUR and EFS. Terminal
events considered were death from any cause for SUR, and
induction death or failure, death in first CR (CCR), and
relapse, whichever came first for EFS. The log-rank test was
used to assess differences in survival curves (Woolson,
1987).
Multivariate analysis was conducted according to the pro-
portional hazard Cox regression model (Cox, 1972) to
evaluate the relative importance of mean AgNOR area in
relation to other known prognostic factors.
Results
In smeared bones marrow blast cells stained by silver, NORs
appeared as well-defined black dots, selectively distributed
throughout the nucleolar area, and more or less regularly
scattered in the lighter stained nuclei. Their quantity was
highly variable, independent of the nuclear size of blast cells
(Figures I and 2).
The mean AgNOR areas of bone marrow cells of the 119
patients ranged from 1.11 to 5.56 jm2; the median and the
mean values were 2.37 and 2.43tim2 respectively. The 119
patients were divided into two groups according to their
AgNOR values, using a cut-off value of 3jIm2, which had
been previously established as the borderline between rapidly
and slowly proliferating tissues (Trere et al., 1991). The first
group, which we considered to be of low proliferation rate,
Figure 1 Smeared marrow blasts from a patient with ALL,
stained by silver for NORs. The nuclear size of blasts is similar to
that of blasts from the patient in Figure 2, but the blasts in
Figure I have more AgNORs than those in Figure 2.
Figure 2 Smeared marrow blasts from a patient with ALL,
stained by silver for NORs.
included 91 children (76%) with a mean AgNOR area of less
than 3 jim2 and a median and mean value of 2.11 jm2 (range
1.11-2.95) and 2.10jIm2 respectively. The second group,
which we considered to be ofhigh proliferation rate, included
28 children (24%) with a mean AgNOR area greater or equal
to 3 jim2 and a median and a mean value of 3.29 tjm2 (range
3.00-5.56) and 3.51 jim2 respectively.
Descriptive statistics relative to the entire population and
the two different groups based on a 3.00jim2 cut-off demon-
strated a normal distribution of the mean AgNOR values.
A total of 112 (94.1%) children entered CR: 97.8% (89/91)
were from the group with low proliferation and 82.1% (23/
28) were from the group with high proliferation. Among the
seven patients who did not achieve CR, two presented a
mean AgNOR area <3jim2 (one death in induction and one
resistant leukaemia) and five presented a mean AgNOR area
>3 jim2 (three resistant and two early death). Eighty-four
patients (72.3%) are still in CCR. There have been three1200 D. TRERE et al.
toxic therapy-related deaths, all in the group of patients with
mean AgNOR areas lower than 3jim', and a total of 14
deaths occurred after resistant or relapsed disease: five in the
group with mean AgNOR areas lower than 3jim' and the
remaining nine in the group with mean AgNOR areas greater
or equal to 3jLm'. Out of a total of 20 deaths the frequency
was significantly higher in the group with mean AgNOR
areas greater than or equal to 3 jLm' (11/28 = 39.3%) com-
pared with that in the group with mean AgNOR areas lower
than 3 fjm2 (9/91 = 9.9%) (P<0.01).
Relapse occurred in 25 out of the 112 children who
achieved CR, mostly in the bone marrow (15 patients) or the
central nervous system (7 patients). The relative frequency in
the lower mean AgNOR area group was 15.7% (14/89),
whereas it reached 47.8% (11/23) in the greater mean
AgNOR areas. Both frequencies of disease recurrence and
mean disease-free time interval in months (19.5 vs 11) were
statistically different in the two groups (P<0.01).
Correlation between AgNOR areas and the main prognos-
tic continuous covariables is reported in Table I. AgNOR
area values were significantly related to bone marrow infil-
tration, measured as per cent of blasts at onset. A Pearson
correlation coefficient value of -0.27 (P<0.005) indicated a
moderate grade of association between an increment of bone
marrow infiltration and decreasing AgNOR area value. A
significant association was also found for age (R = 0.25;
P<0.05) haemoglobin (R = 0.27; P<0.01) WBC (white
blood cell) count and hepatomegaly, while none of the other
variables considered (absolute peripheral blast cells count,
platelet count and splenomegaly) was correlated with
AgNOR values.
The comparison between mean AgNOR area and both
immunophenotype (T-ALL versus others) and FAB morpho-
logy (LI versus L2) revealed significantly higher values of
AgNORs in both T- and L2-ALL. No difference in distribu-
tion was revealed by Student's t-test according to sex (Table
II). Nor was a significant association shown between mean
AgNOR area and central nervous system leukaemia at onset,
nephromegaly, skeletal lesions, massive adenomegaly, initial
prednisone response and protocol treatment.
After a median follow-up time of 26 months, the 3 year
overall survival (SUR) estimate for the 119 patients was
71.3%. SUR estimate was 85.9% for the group of patients
Table I Correlation analysis between bone marrow AgNOR values
and prognostic factors as continuous variables ordered by
descending importance
AgNOR area
Pearson correlation
coefficient P
Bone marrow infiltration -0.27 <0.005
(percentage of blasts)
Age (years) +0.24 <0.01
Haemoglobin (g dl-') +0.20 <0.05
White blood cell count +0.20 <0.05
( x 10 1)
Peripheral blasts +0.17 NS
(X 1091l-)
Platelets ( x 109 1-l) +0.14 NS
Hepatomegaly (cm) +0.22 <0.05
Splenomegaly (cm) +0.12 NS
Table II Comparison of AgNOR mean values in subgroups
identified by categorical prognostic factors ordered by descending
importance
Mean AgNOR
Variables Subgroups area (gm-) t P
Immunophenotype T-cell 2.92 2.76 <0.005
Non-T-cell 2.36
Fab morphology Li 2.33 2.55 <0.005
L2 2.92
Sex Female 2.51 0.99 NS
Male 2.36
with a mean AgNOR area <3 gm' and 47.0% in the group
ofpatients with a mean AgNOR area > 3 jim2 (log-rank test
11.8; P<0.001). The 3 year EFS estimate was 61.2% for all
119 patients: 66.2% for patients with AgNOR area <3 jm2
and 41.2% for patients with AgNOR area > 3 jim', with a
significant difference between the two curves (log-rank test
16.36; P<0.001) (Figure 3).
We also calculated the 3 year EFS probability for sub-
groups ofpatients according to ranks previously reported for
each variable. Features that had an adverse effect on EFS in
the whole group included, apart from mean AgNOR area
>3 jm2, T-cell immunophenotype, mediastinal mass, L2
FAB morphology and leucocyte count above 20 x 1091-'
(Table III). No significance was reached for P log-rank
analysis for age (<1 year, 1-9 years, 10-14 years) central
nervous system involvement (yes versus no), sex (M versus
F), hepatomegaly (yes versus no), kidney involvement (yes
versus no), platelet count (<50 x 1091-' vs >50 x 1091-'),
haemoglobin (<10 g dl-' vs > Ogdl-'), prednisone res-
ponse (yes versus no) and protocol generation (87 versus
others).
Multivariate analysis using the Cox regression model on
more consolidated clinical and biological variables showed
that mean AgNOR area was the only independent predictor
of unfavourable EFS probability (P<0.01). None of the
other variables considered in this model, and listed in Table
IV in order of importance, reached the statistical significance
level of 5%. WBC count in particular was not demonstrated
to be an independent prognostic factor in predicting EFS
probability in this group of patients even if a cut-off such as
20,000 or 100,000 was considered.
Discussion
The present results show that the number of interphase
AgNORs of marrow cell leukaemic lymphoblasts, at the time
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Figure 3 Estimated EFS curves according to AgNOR area.
Table III Impact of patient biological and clinical features on
event-free survival
No. (%) Three year EFS P
Prognostic factors ofpatients (%) (SE) (log-rank)
AgNOR area (tmM2)
<3 91 (76%) 66.2 (7.9) 0.0001
>3 28 (24%) 41.2 (9.5)
Immunophenotype
T-cell 17 (14%) 39.7 (12.2) 0.0001
Non-T-cell 101 (86%) 65.1 (6.8)
Mediastinal mass
Yes 6 (5%) 16.7 (15.2) 0.0001
No 112 (95%) 63.5 (6.5)
FAB morphology
LI 92 (81%) 63.0 (7.4) 0.003
L2 21 (19%) 43.0 (11.8)
Leucocyte count (1091-1)
<20 69 (59%) 65.4 (9.0) 0.01
>20 47 (41%) 56.8 (8.2)
. 0%10%
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Table IV Relative importance of factors predicting event-free
survival considered together by multivariate analysis according to
Cox regression model for life table data
Order of importance
(unfavourable.favourable) Chi-square P
AgNOR area (flm2)
> 3:<3 6.23 0.01
Mediastinal mass
Yes:no 1.53 0.21 NS
Leucocyte count (1O1 1-')
>20:<20 0.80 0.37 NS
Immunophenotype
T-cell: non-T-cell 0.40 0.52 NS
FAB morphology
L2:L1 0.26 0.61 NS
of presentation, was related to the progression of the disease
in our series of 119 children with ALL. The group ofpatients
(n = 28) with a mean AgNOR value greater than 3 jim2 was
characterised by a higher number of deaths, more frequent
incidence of relapse and shorter time interval to relapse than
the group of patients (n = 91) with AgNOR area value lower
than 3 fjm2. All these differences were statistically highly
significant.
Interphase AgNORs are those nucleolar components in
which ribosomal genes are located (Hernandez-Verdun, 1983;
Goessens, 1984). Their silver stainability is due to the
presence of a specific group of acidic proteins which are
necessary for ribosomal RNA synthesis (Howell, 1982). The
quantity of interphase Ag ORs greatly increases in the cell
stimulated to proliferate. The maximum AgNOR value is
reached during the S-phase (Pession et al., 1991). In cancer
tissues it has been demonstrated that the quantitative dis-
tribution of AgNORs is related to the values obtained using
other well-established parameters of cell kinetics such as Ki67
LI (labelling index), bromodeoxyuridine labelling index
(BrdU LI) and percentage of S-phase cells determined by
flow cytometry (Derenzini & Trere, 1991). Numerous studies
carried out on human tumour cells cultured in vitro have
shown that the number of AgNORs is strictly and directly
related to cell doubling time (Derenzini et al., 1989, 1990;
Trere et al., 1989; Hara et al., 1991; Ofner et al., 1992).
Indeed, ribosomal biogenesis necessary for cell duplication is
restricted to a shorter period in rapidly dividing cells than in
slowing dividing cells with a consequently greater expression
of AgNORs in the faster proliferating cells. Interphase
AgNOR quantification therefore represents a unique tool to
evaluate the rapidity of cell proliferation in routinely pro-
cessed cytohistological samples. According to the relationship
between AgNOR quantity and doubling time of cells cul-
tured in vitro (Trere et al., 1989), the AgNOR values of
marrow leukaemic lymphoblasts observed in the present
study were consistent with a long doubling time of these
cells. The mean AgNOR value of the 119 patients with ALL
(2.43 jLm2) would in fact correspond to a doubling time
greater than 100 h. Comparison of the AgNOR quantitative
distribution with the pretreatment prognostic factors which
are currently used for defining low- and high-risk patients
showed that AgNOR values were positively correlated with
age, haemoglobin concentration, WBC count and hepato-
megaly. The mean AgNOR quantity was greater in the
patients with T-cell surface markers than in the non-T group
and in L2 than in LI blasts. An inverse correlation was
found between the entity of bone marrow infiltration by
blasts and AgNOR values. The latter finding is not surpris-
ing: it might be reasonably suggested that the proliferative
activity of cancer cells is probably lowered as the neoplastic
tissue totally occupies the marrow space.
Other features of the disease, at the time of diagnosis,
which have a statistically significative impact on event-free
survival of children were, apart from AgNOR value, the
immunophenotype and FAB morphology of blasts, the pre-
sence of mediastinal tumour mass and leucocyte count. Mul-
tiple regression analysis showed that these four parameters
are not independent prognostic factors. Only AgNOR value
was found to be significantly correlated with the length of
event-free survival. This observation is consistent with the
correlation between AgNOR value and the single prognostic
factors (Table I and II).
The present findings, obtained from a larger number of
patients, were consistent with those reported by Scarffe et al.
(1980) and Dow et al. (1982) on the relationship between the
proliferative activity of marrow lymphoblasts and the dura-
tion of first remission in childhood ALL. These authors
found that patients with >6% S-phase cells, measured by
either [3H]thymidine incorporation (Dow et al., 1982) or
DNA flow cytometry (Scarffe et al., 1980), had a shorter
median length of remission than those <6% S-phase cells. In
these studies the cell kinetics parameters represented, together
with the WBC count, the most powerful prognostic predic-
tors. In the series of patients considered by us, the WBC
count lost its significance in the multiple regression analysis.
This might have been due either to different therapeutic
regimens reducing the prognostic impact of WBC count or/
and to the fact that in our study the cell kinetics parameter
evaluated was not exactly the same as that measured by
Scarffe et al. (1980) and Dow et al. (1982). AgNOR value
indicates the rapidity of cell proliferation, which is different
from the percentage of S-phase cells. Even if these two
parameters have been shown to be statistically related
(Crocker et al., 1988; Tanaka et al., 1989; Orita et al., 1990;
Trere et al., 1991), they cannot be considered to be superim-
posable. The duration of S-phase has been demonstrated to
be variable in marrow leukaemic lymphoblasts, and its value
has not always been related to the cell doubling time
(Nakamura et al., 1991).
The present findings have demonstrated that cell prolifera-
tion is a reliable prognostic parameter in childhood ALL and
indicate the opportunity to routinely add cell kinetics evalua-
tion to the other well-established parameters for pretreatment
prognostic definition of ALL. Among the methods used for
cell kinetics measurement those methods ought to be prefer-
red which evaluate the rapidity of cell proliferation rather
than the number of cycling cells. Indeed, it is the former
parameter which indicates more precisely the actual growth
rate of the neoplastic mass. The importance ofthe rapidity of
cell leukaemic lymphoblast proliferation for the clinical
course of ALL can be related to the fact that: (1) if the
therapeutic efficacy is the same, the length of the remission
would be determined by the degree of cell proliferation rate
and (2) drug resistance may develop more quickly in rapidly
than in slowly proliferating cells (Scarffe et al., 1980).
Apart from the AgNOR parameter, which has only
recently been introduced into tumour pathology for cell
kinetics evaluation, cell cycle time length can be precisely
measured by DNA flow cytometry (Dolbeare et al., 1983).
This procedure, however, necessitates the in vivo infusion of
BrdU and the exclusive utilisation of one whole-bone mar-
row aspirate. AgNOR quantification is carried out on a
smeared preparation using only a small portion of the biopsy
material employed for routine characterisation of the
leukaemic marrow infiltrate.
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